» Articles » PMID: 19077543

Block of Tetrodotoxin-sensitive, Na(V)1.7 and Tetrodotoxin-resistant, Na(V)1.8, Na+ Channels by Ranolazine

Overview
Specialty Biochemistry
Date 2008 Dec 17
PMID 19077543
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence supports a role for the tetrodotoxin-sensitive Na(V)1.7 and the tetrodotoxin-resistant Na(V)1.8 in the pathogenesis of pain. Ranolazine, an anti-ischemic drug, has been shown to block cardiac (Na(V)1.5) late sodium current (I(Na)). In this study, whole-cell patch-clamp techniques were used to determine the effects of ranolazine on human Na(V)1.7 (hNa(V)1.7 + beta(1) subunits) and rat Na(V)1.8 (rNa(V)1.8) channels expressed in HEK293 and ND7-23 cells, respectively. Ranolazine reduced hNa(V)1.7 and rNa(V)1.8 I(Na) with IC50 values of 10.3 and 21.5 microM (holding potential = -120 or -100 mV, respectively). The potency of I(Na) block by ranolazine increased to 3.2 and 4.3 microM when 5-sec depolarizing prepulses to -70 (hNa(V)1.7) and -40 (rNa(V)1.8) mV were applied. Ranolazine caused a preferential hyperpolarizing shift of the steady-state fast, intermediate and slow inactivation of hNa(V)1.7 and intermediate and slow inactivation of rNa(V)1.8, suggesting preferential interaction of the drug with the inactivated states of both channels. Ranolazine (30 microM) caused a use-dependent block (10-msec pulses at 1, 2 and 5 Hz) of hNa(V)1.7 and rNa(V)1.8 I(Na) and significantly accelerated the onset of, and slowed the recovery from inactivation, of both channels. An increase of depolarizing pulse duration from 3 to 200 msec did not affect the use-dependent block of I(Na) by 100 microM ranolazine. Taken together, the data suggest that ranolazine blocks the open state and may interact with the inactivated states of Na(V)1.7 and Na(V)1.8 channels. The state-and use-dependent modulation of hNa(V)1.7 and rNa(V)1.8 Na+ channels by ranolazine could lead to an increased effect of the drug at high firing frequencies, as in injured neurons.

Citing Articles

Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels.

Djamgoz M Br J Cancer. 2024; 130(9):1415-1419.

PMID: 38424164 PMC: 11058819. DOI: 10.1038/s41416-024-02622-w.


Tetrodotoxin-Sensitive Neuronal-Type Na Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation.

Munger M, Olgar Y, Koleske M, Struckman H, Mandrioli J, Lou Q J Am Heart Assoc. 2020; 9(11):e015119.

PMID: 32468902 PMC: 7429002. DOI: 10.1161/JAHA.119.015119.


Atrial-ventricular differences in rabbit cardiac voltage-gated Na currents: Basis for atrial-selective block by ranolazine.

Caves R, Cheng H, Choisy S, Gadeberg H, Bryant S, Hancox J Heart Rhythm. 2017; 14(11):1657-1664.

PMID: 28610990 PMC: 5666337. DOI: 10.1016/j.hrthm.2017.06.012.


Ranolazine Therapy Reduces Non-ST-Segment-Elevation Myocardial Infarction and Unstable Angina in Coronary Disease Patients with Angina.

Murray G, Colombo J Int J Angiol. 2016; 25(3):159-64.

PMID: 27574382 PMC: 5001871. DOI: 10.1055/s-0036-1572364.


A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.

Cheng F, Zhao J, Fooksa M, Zhao Z J Am Med Inform Assoc. 2016; 23(4):681-91.

PMID: 27026610 PMC: 6370253. DOI: 10.1093/jamia/ocw007.